Geneticist Yuancheng Lu Develops Age-Reversal Tech for Vision Restoration

Geneticist Yuancheng Lu is developing age-reversal technologies with a specific focus on restoring vision, driven by personal and familial experiences with age-related eye conditions. Lu, 34, works at the Whitehead Institute in Cambridge, Massachusetts, and is motivated by a family history of age-related blindness, including a great-aunt in China who was killed due to vision impairment. His own genetic testing revealed a mutation for macular degeneration, a leading cause of vision loss in older adults, and he also takes precautions against sunlight exposure, a known risk factor. Lu views the eye as a "unique system to study aging and rejuvenation," believing it offers significant potential for breakthroughs in these fields.

In 2018, while pursuing his PhD at Harvard Medical School, Lu achieved a significant milestone in rejuvenation science by successfully repairing the optic nerves of mice using a reprogramming technique. This experiment involved inducing blindness in mice by crushing their optic nerves and subsequently injecting the cells with a gene therapy designed to revert them to a youthful state. Within sixteen days, the optic nerves demonstrated regrowth, with axons visible under a microscope as "spidery orange filaments." Further testing, which involved observing the mice's ability to track changes in a box with rotating bars of light, confirmed that the treated mice regained their sight.

David Sinclair, a longevity scientist and head of Lu's lab at the Whitehead Institute, recognized the profound implications of Lu's findings, recalling Lu's text message with the images and his own response, "I see the future." This groundbreaking work in mice has now transitioned to human clinical trials. On June 9, Life Biosciences, a startup co-founded by Sinclair in which Lu holds a minor ownership stake, announced the commencement of human trials for the gene therapy. The treatment has been injected into the eyes of participants, marking a critical step towards potentially treating age-related vision loss in humans. The development represents a significant advancement in the application of age-reversal techniques beyond theoretical research into tangible therapeutic interventions.